Cargando…

Long-term treatment results and prognostic factors of synchronous and metachronous squamous cell carcinoma of head and neck and esophagus

BACKGROUND: The purpose was to investigate the prognosis of patients with synchronous and metachronous squamous cell carcinoma of head and neck (HNSCC) and esophagus (ESCC), and to evaluate the prognostic factors of these patients. METHODS: A retrospective review was performed on 70 patients with sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiali, Shen, Chunying, Hu, Chaosu, Wang, Cuihong, Zhu, Yongxue, Lu, Xueguan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797312/
https://www.ncbi.nlm.nih.gov/pubmed/35117178
http://dx.doi.org/10.21037/tcr.2019.12.81
Descripción
Sumario:BACKGROUND: The purpose was to investigate the prognosis of patients with synchronous and metachronous squamous cell carcinoma of head and neck (HNSCC) and esophagus (ESCC), and to evaluate the prognostic factors of these patients. METHODS: A retrospective review was performed on 70 patients with synchronous and metachronous HNSCC and ESCC treated in our institution from January 2005 to December 2016. Kaplan-Meier method and Cox proportional hazard model were used to evaluate overall survival (OS) and determine the prognostic factors associated with survival outcomes. RESULTS: The 1-, 2- and 3-year OS rates were 77.1%, 57.1% and 37.1% with the median survival time for 33.5 months. The univariate analysis results revealed that the patients with early-stage of ESCC, metachronous cancer, and receiving surgery for both cancer had better OS (P=0.003; P=0.035; P=0.002). The multivariate analysis showed that the clinical stage of ESCC and receiving surgery for both cancer or not were the independent prognostic factors for OS. CONCLUSIONS: The multidisciplinary treatment outcome is acceptable, especially for patients with early clinical stage ESCC and with chance to receiving surgery for both cancer.